Corvus Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Corvus Pharmaceuticals has been growing earnings at an average annual rate of 6.8%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
6.8%
Earnings growth rate
21.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -69.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Mar 06
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Oct 23Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
May 16Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Dec 05Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Sep 26We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
Aug 14Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
Apr 05We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Dec 15Checking In On Corvus Pharmaceuticals
Dec 10Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Sep 22We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Aug 26Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target
May 27Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
May 08The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Feb 19Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Feb 07Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Dec 16Corvus Pharmaceuticals EPS misses by $0.06
Oct 29Revenue & Expenses BreakdownBeta
How Corvus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -27 | 7 | 17 |
| 30 Sep 23 | 0 | -30 | 7 | 17 |
| 30 Jun 23 | 0 | -39 | 7 | 23 |
| 31 Mar 23 | 0 | -41 | 7 | 24 |
| 31 Dec 22 | 0 | -41 | 8 | 24 |
| 30 Sep 22 | 0 | -41 | 8 | 25 |
| 30 Jun 22 | 0 | -37 | 8 | 22 |
| 31 Mar 22 | 0 | -40 | 8 | 26 |
| 31 Dec 21 | 0 | -43 | 9 | 29 |
| 30 Sep 21 | 0 | -7 | 10 | 32 |
| 30 Jun 21 | 0 | -6 | 11 | 31 |
| 31 Mar 21 | 0 | -5 | 12 | 30 |
| 31 Dec 20 | 0 | -6 | 12 | 32 |
| 30 Sep 20 | 0 | -44 | 12 | 34 |
| 30 Jun 20 | 0 | -46 | 11 | 36 |
| 31 Mar 20 | 0 | -48 | 11 | 39 |
| 31 Dec 19 | 0 | -47 | 11 | 38 |
| 30 Sep 19 | 0 | -46 | 11 | 37 |
| 30 Jun 19 | 0 | -46 | 11 | 37 |
| 31 Mar 19 | 0 | -44 | 11 | 36 |
| 31 Dec 18 | 0 | -47 | 11 | 39 |
| 30 Sep 18 | 0 | -48 | 10 | 40 |
| 30 Jun 18 | 0 | -51 | 10 | 42 |
| 31 Mar 18 | 0 | -54 | 10 | 45 |
| 31 Dec 17 | 0 | -56 | 10 | 46 |
| 30 Sep 17 | 0 | -55 | 10 | 46 |
| 30 Jun 17 | 0 | -52 | 10 | 43 |
| 31 Mar 17 | 0 | -46 | 9 | 37 |
| 31 Dec 16 | 0 | -36 | 8 | 29 |
| 30 Sep 16 | 0 | -31 | 7 | 24 |
| 30 Jun 16 | 0 | -24 | 5 | 19 |
| 31 Mar 16 | 0 | -36 | 4 | 14 |
| 31 Dec 15 | 0 | -31 | 2 | 11 |
| 30 Sep 15 | 0 | -25 | 1 | 6 |
Quality Earnings: CRVS is currently unprofitable.
Growing Profit Margin: CRVS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRVS is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare CRVS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRVS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CRVS has a negative Return on Equity (-69.87%), as it is currently unprofitable.